{
  "context": {
    "rules": [
      "Rule1: Provided that production of drug1 is authorized in region1, if the patent for drug1 is approved in region1, then drug1 is available in the market of region1.",
      "Rule2: Export of drug1 is approved in region1, or if drug1 is a banned substance in region1, then it is not blacklisted in region1.",
      "Rule3: Either import of drug1 is restricted in region1, or export of drug1 is not approved in region1.",
      "Rule4: Under the condition that drug1 is a controlled substance in region1, it is not blacklisted in region1.",
      "Rule5: If drug1 is authorized for emergency use in region1, then it has temporary approval in region1.",
      "Rule6: Provided that fast-track review for drug1 is conducted by job1, drug1 has accelerated approval in region1.",
      "Rule7: Either fast-track review for drug1 is conducted by job1, or drug1 does not have temporary approval in region1.",
      "Rule8: Whenever drug1 has accelerated approval in region1, it has conditional marketing approval in region1.",
      "Rule9: Under the condition that research for drug1 is completed by job1, either drug1 is approved in region1, or it is available in the market of region1.",
      "Rule10: Provided that regulatory priority for drug1 is assigned to job1, if drug1 has accelerated approval in region1, then it does not have conditional marketing approval in region1.",
      "Rule11: If drug1 is subject to an international ban in region1, then export of drug1 is not approved in region1.",
      "Rule12: Either investment for drug1 is protected by financial_product1, or market withdrawal for drug1 is not initiated by financial_product1.",
      "Rule13: Provided that there is a supply shortage of drug1 in region1, production of drug1 is halted in region1.",
      "Rule14: If there is a manufacturing issue with drug1 in region1, then production of drug1 is authorized in region1.",
      "Rule15: Under the condition that regulatory investigation for drug1 is conducted by job1, either there is a supply shortage of drug1 in region1, or there is a manufacturing issue with drug1 in region1.",
      "Rule16: Either regulatory investigation for drug1 is conducted by job1, or compliance audit for drug1 is performed by job1.",
      "Rule17: If compliance audit for drug1 is performed by job1, then quality control review for drug1 is done by job1.",
      "Rule18: Whenever quality control review for drug1 is done by job1, either there is a supply shortage of drug1 in region1, or there is a manufacturing issue with drug1 in region1.",
      "Rule19: If manufacturing for drug1 is approved in region1, then drug1 has passed clinical trials.",
      "Rule20: Under the condition that regulatory submission for drug1 is made by financial_product1, if research for drug1 is not completed by job1, then manufacturing for drug1 is approved in region1.",
      "Rule21: Either regulatory submission for drug1 is made by financial_product1, or compliance review for drug1 is conducted by job1.",
      "Rule22: If compliance review for drug1 is conducted by job1, then safety assessment for drug1 is performed by job1.",
      "Rule23: Market analysis for drug1 is done by financial_product1, or if safety assessment for drug1 is performed by job1, then provided that research for drug1 is not completed by job1, manufacturing for drug1 is approved in region1.",
      "Rule24: If it is not the case that if drug1 is a banned substance in region1, then it is a controlled substance in region1, then drug1 is authorized for emergency use in region1.",
      "Rule25: Provided that it is not the case that if there are safety concerns for drug1 in region1, then drug1 is subject to an international ban in region1, market withdrawal for drug1 is initiated by financial_product1.",
      "Rule26: If it is not true that if drug1 is subject to price regulation in region1, then reimbursement for drug1 is approved in region1, then drug1 is under free market pricing in region1.",
      "Rule27: If it is not the case that it is not the case that if production of drug1 is not authorized in region1, then generic competition for drug1 exists from financial_product1, then the patent for drug1 has expired in region1, then drug1 is subject to price regulation in region1.",
      "Rule28: Provided that it is not the case that if production of drug1 is not authorized in region1, then generic competition for drug1 exists from financial_product1, the patent for drug1 has not expired in region1.",
      "Rule29: If production of drug1 is not authorized in region1, then drug1 is blacklisted in region1.",
      "Rule30: Under the condition that production of drug1 is not authorized in region1, drug1 is a banned substance in region1.",
      "Rule31: If production of drug1 is not authorized in region1, then generic competition for drug1 does not exist from financial_product1."
    ],
    "facts": [
      "Fact1: Regulatory priority for drug1 is assigned to job1.",
      "Fact2: There are safety concerns for drug1 in region1.",
      "Fact3: The patent for drug1 is approved in region1.",
      "Fact4: It is not the case that drug1 is approved in region1.",
      "Fact5: Import of drug1 is not restricted in region1.",
      "Fact6: Investment for drug1 is not protected by financial_product1.",
      "Fact7: Production of drug1 is not halted in region1.",
      "Fact8: Drug1 has not passed clinical trials.",
      "Fact9: Reimbursement for drug1 is not approved in region1.",
      "Fact10: Drug1 is not under free market pricing in region1.",
      "Fact11: Market analysis for drug1 is not done by financial_product1."
    ]
  },
  "question": "Drug1 is available in the market of region1."
}